Clinical trials: Retinal Disorders
Age-Related Macular Degeneration
Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population
The aim of the study is to show a higher expression of the Y402H polymorphism in the complement factor H in patients with AMD compared to healthy individuals.
- Trial name
- NCT00533754
- Testing
- drawing blood
- Where
- Austria
- Sponsor
- Rudolf Foundation Clinic
Macular Degeneration
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
The purpose of this study is to explore the combination of PDT with verteporfin at reduced and standard fluence rates, in conjunction with bevacizumab, in the treatment of subfoveal CNV of all subtypes with a high percentage of…
- Trial name
- NCT00403442
- Testing
- Verteporfin Therapy/ Drug: Bevacizumab
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Retinitis Pigmentosa, Cone Rod Dystrophy
Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy
This study evaluates the safety and effectiveness of the Intelligent Retinal Implants System (IRIS V1)
- Conditions
- Retinitis Pigmentosa, Cone Rod Dystrophy, Choroideremia
- Trial name
- IRIS-1 (NCT01864486)
- Testing
- Intelligent Retinal Implant System
- Where
- 5 sites in Austria, France and 1 more
- Volunteers
- 20 people
- Sponsor
- Science Corporation
Macular Edema
Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery
Assess prophylactic efficacy of topical non-steroidal anti-inflammatory drops in preventing macular edema. Patient undergoing uncomplicated cataract surgery will be enrolled and randomized to nepafenac, ketorolac, or placebo.
- Trial name
- PNK (NCT01395069)
- Testing
- Nepafenac 0.1%, Ketorolac 0.5%
- Where
- Canada
- Volunteers
- 162 people
- Sponsor
- Queen's University
Retinal Disease, Healthy Eyes
Evaluation of the Heidelberg Engineering SPECTRALIS With Flex Module for In-vivo Imaging in the Supine Position
This is a prospective clinical study conducted at one clinical site in the United States.
- Trial name
- NCT04661124
- Testing
- SPECTRALIS, SPECTRALIS with Flex Module
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Heidelberg Engineering GmbH
Proliferative Diabetic Retinopathy
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
Phase III study comparing monthly octreotide i.m. in comparison to no additional treatment in patients with proliferative diabetic retinopathy after lasercoagulation.
- Trial name
- NCT00170742
- Testing
- Octreotide, 30 mg i.m. LAR formulation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Novartis
Diabetic Retinopathy
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic…
- Trial name
- CANBERRA (NCT04265261)
- Testing
- RG7774
- Where
- 68 sites in United States, Australia and 5 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type II
Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
This is a prospective, randomized, active control, two-arm parallel, double-blind, monocenter phase IV clinical trial. The trial compares empagliflozin to glimepiride in patients with type 2 diabetes mellitus in addition to…
- Trial name
- NCT02985242
- Testing
- Empagliflozin, Glimepiride
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Hannover Medical School
Retinitis Pigmentosa, Cone-Rod Dystrophy
IRIS PILOT - Extended Pilot Study With a Retinal Implant System
Investigate whether blind subjects that fulfil the patient criteria provided with a Retinal Implant are able to differentiate between simple patterns like horizontal bar, vertical bar and cross.
- Conditions
- Retinitis Pigmentosa, Cone-Rod Dystrophy, Choroideremia
- Trial name
- NCT00427180
- Testing
- Retinal Implant System (IRIS)
- Volunteers
- 20 people
- Sponsor
- Intelligent Medical Implants GmbH
Retinitis Pigmentosa
Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
The purpose of this study is to evaluate the short-term safety of a single intravitreal injection of autologous bone marrow stem cells in patients with retinitis pigmentosa.
- Trial name
- NCT01068561
- Testing
- intravitreal injection of autologous bone marrow stem cells
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- University of Sao Paulo
Alzheimer Disease
Eye to Brain Connection
This is a non-randomized, non-treatment, observational study designed to discover correlations between retinal imaging and amyloid PET imaging. Subjects will be recruited to the clinical cohort from referring physicians.
- Trial name
- NCT05215782
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Optina Diagnostics Inc.
Age-Related Macular Degeneration, Genetic Testing
The Moran AMD Genetic Testing Assessment Study
The goals of this study are: To assess the impact of genetic testing for Age-related Macular Degeneration (AMD) on lifestyle behaviors as measured by systemic and ocular carotenoid status.
- Conditions
- Age-Related Macular Degeneration, Genetic Testing, Nutritional Biomarkers
- Trial name
- MAGENTA (NCT05265624)
- Testing
- Early disclosure of genetic testing results, Late disclosure of genetic testing results
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Paul S. Bernstein
Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular…
- Conditions
- Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
- Trial name
- NCT02599064
- Testing
- RXI-109
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- RXi Pharmaceuticals, Corp.
Retinal Detachment
The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body
The purpose of this study is to determine the feasibility, primary safety and efficacy of foldable capsular vitreous body (FCVB) in the treatment of retinal detachment.
- Trial name
- NCT00910702
- Testing
- foldable capsular vitreous body(FCVB)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- GuangZhou WeiShiBo Biotechnology Co., ltd
Proliferative Diabetic Retinopathy, Photocoagulation Burn to Retina
New Pattern of Retinal Laser Treatment for PDR
The objective of the study is to evaluate the efficacy of a new pattern of argon-laser in treating patients with proliferative diabetic retinopathy (PDR).
- Trial name
- NCT07315802
- Testing
- A new pattern of retinal laser
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Macular Holes, Retinal Detachment
A Study of a New Surgical Treatment of Macular Hole Retinal Detachment in High Myopia
This study evaluates the surgical outcomes of inverted internal limiting membrane insertion combined with air tamponade in the treatment of macular hole retinal detachment (MHRD) in high myopia, and also to compare the treatment…
- Conditions
- Macular Holes, Retinal Detachment, High Myopia
- Trial name
- NCT03383731
- Testing
- Group 1, Group 2
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Diabete Mellitus, Retina Vein Occlusion
Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab
Bevacizumab, an anti-VEGF (vascular endothelial growth factor) agent used in the treatment of diabetic retinopathy and macular edema associated with retinal vein occlusion, is commonly administered in ophthalmology clinics…
- Conditions
- Diabete Mellitus, Retina Vein Occlusion, Age Macular Degeneration
- Trial name
- NCT07550777
- Testing
- blood test
- Where
- Turkey (Türkiye)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Aging, Age-Related Macular Degeneration
Investigation of Macular Pigment Augmentation on Dark Adaptation
The study will evaluate whether taking a nutritional supplement designed to increase macular pigment in the eye can improve a person's ability to adjust to darkness.
- Trial name
- NCT00478439
- Testing
- ZeaVision EyePromise Restore, Multivitamin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Extensive Macular Atrophy With Pseudodrusen (EMAP), Retinitis Pigmentosa (RP)
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases
his prospective, comparative pilot study investigates the safety and functional outcomes of subtenon autologous platelet-rich plasma (PRP) in patients with Retinitis Pigmentosa (RP) and Extensive Macular Atrophy with…
- Trial name
- RETINA-PRP (NCT07341919)
- Testing
- Subtenon Injection of Autologous Platelet-Rich Plasma
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Rubens Camargo Siqueira
Neovascular Age-related Macular Degeneration
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
The primary objective is to assess long-term safety and tolerability of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in patients with neovascular AMD.
- Trial name
- NCT00964795
- Testing
- Intravitreal Aflibercept Injection 2mg
- Where
- 124 sites in United States, Canada
- Volunteers
- 323 people
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.